Rivaroxaban for heart clots in children
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a blood clot inside the heart, confirmed by an echocardiogram and another imaging test (like an MRI or CT scan).
- You or your child's legal guardian must sign a consent form agreeing to participate.
- Your child must have been born at full term (38 weeks or more of pregnancy).
- Your child must have been taking milk or food by mouth for at least 10 days and weigh at least 2.6 kilograms (about 5.7 pounds).
- In the past 10 days, your child must not have had any major bleeding problems or abnormal blood clotting test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a blood thinner called rivaroxaban is used in babies under 2 who have had a blood clot. It aims to understand safety and patterns of use to help guide treatment for young children.
This trial is testing the drug rivaroxaban in children aged 2 to 17 who have large bulges (aneurysms) in their heart arteries after Kawasaki disease. It aims to see how the drug works in the body to prevent blood clots.
This trial studies whether rivaroxaban (a blood thinner) can help prevent dangerous clots in children age 2 and older who have “giant” coronary artery aneurysms after Kawasaki disease. Doctors will see if it’s safe and tolerable for children who are also on standard anti-clot/anti-platelet medications for the next 3 months.
This trial studies whether a specific blood thinner can better treat a left-side heart clot found soon after a heart attack. It may help prevent the clot from getting worse or causing complications.
This trial tests if the blood thinner rivaroxaban can prevent strokes in people with hypertrophic cardiomyopathy who have early signs of damage in their left atrium (the heart's upper chamber). You may qualify if you have this condition, are in a normal heart rhythm, and are between 40 and 80 years old.
This study tests the best dose of a blood thinner called rivaroxaban for children with a giant coronary artery aneurysm after Kawasaki disease. The goal is to prevent dangerous blood clots.
Hear when a new Intracardiac Thrombus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.